Sarepta falls on additional DMD data

Sarepta Therapeutics Inc. (NASDAQ:SRPT) fell $3.35 (13%) to $22.54 on Thursday after reporting data some analysts said raise questions about the long-term efficacy of eteplirsen ( AVI-4658) for Duchenne muscular dystrophy. In 10 patients, eteplirsen led to a 27.5 meter reduction in mean six-minute walk test (6MWT) from baseline to week 144 compared with a 100.7 meter reduction for patients who received placebo for 24 weeks followed by eteplirsen for an additional 120 weeks (p=0.006).

In January, Sarepta said eteplirsen for 120 weeks led to a 9.8 meter reduction in mean 6MWT from baseline to week 120 compared to a 67.8 meter mean reduction for patients who received placebo for 24 weeks followed by eteplirsen for an additional 96 weeks (p=0.016). The data came from boys aged 7-13, a range when DMD patients typically experience progressive walking difficulty. ...